ICD code D22.9 is used to identify an unspecified melanocytic nevus, commonly known as a mole, for accurate medical recordkeeping.
ICD code D22.9 is a diagnosis for a melanocytic nevus (commonly known as a mole) that is not specified as to its exact type or location.
1. Presence of a pigmented skin lesion or mole with no definitive clinical or histopathological features distinguishing it as a specific type of melanocytic nevus
2. Lesion is benign in appearance, without signs of malignancy such as asymmetry, irregular borders, color variation, diameter greater than 6mm, or evolving characteristics
3. No evidence of dysplasia, atypia, or malignant transformation upon clinical evaluation
4. Lesion is not associated with any specific anatomical site or subtype of melanocytic nevus
5. Patient history and examination do not indicate trauma, infection, or other secondary changes to the lesion
6. Diagnosis is based on visual inspection and/or dermatoscopic findings consistent with a benign melanocytic proliferation, but lacking further specification
Relevant CPT codes for ICD code D22.9 include:
- 11102: Tangential biopsy of skin; single lesion
- 11103: Tangential biopsy of skin; each separate/additional lesion
- 11104: Punch biopsy of skin; single lesion
- 11105: Punch biopsy of skin; each separate/additional lesion
- 11106: Incisional biopsy of skin; single lesion
- 11107: Incisional biopsy of skin; each separate/additional lesion
- 11400–11406: Excision, benign lesion including margins, trunk, arms, or legs (size-based)
- 11420–11426: Excision, benign lesion including margins, scalp, neck, hands, feet, genitalia (size-based)
- 11440–11446: Excision, benign lesion including margins, face, ears, eyelids, nose, lips (size-based)
- 17110: Destruction of benign lesions (up to 14 lesions)
- 17111: Destruction of benign lesions (15 or more lesions)
Schedule a demo to see how MD Clarity’s RevFind software can read your contracts and automatically detect underpayments for CPT codes related to ICD code D22.9. Discover how easy it is to identify missed revenue opportunities and ensure accurate reimbursement with RevFind.

